Results on Merck's new painkiller draw mixed reviews
14th Nov 2006, 00:00 GMT
CHICAGO - The first published studies of Arcoxia, the drug that New Jersey-based Merck & Co. hopes will take the place of its withdrawn painkiller Vioxx, are getting mixed reviews from doctors, some of whom say the results do not make a case for the medication's approval.
Results on Merck's new painkiller draw mixed reviews related news:
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
- Mixed reviews for Vioxx successor — MSNBC.com: Health
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
Latest news from New Jersey News:
- GOLDBERG ON FOOTBALL: Bears bide their time, overrun the Giants
- Bears 38, Giants 20
- GOLDBERG ON FOOTBALL: Bears bide their time, overrun Giants
- Bears take 24-20 lead over Giants after 3 quarters
- Hester ties NFL record with 108-yard missed field goal return
- Bears 31, Giants 20
- Ocean Power Technologies files for IPO of up to $100M
- Jane Street co-founder donates $1 million to cure paralysis
- Fellow legislators approve inquiry into one of their own
- Feds: Corruption continues at UMDNJ